Rivaroxaban
Di Redazione | 28 Luglio 2023 | 0
Ultima modifica: 25 Settembre 2024
Rivaroxaban (Xarelto®) è un farmaco attivo con circa l’80% di biodisponibilità per uso orale....
CLOT+ RSS Feed- Evidence-based risk stratification of patients with acute pulmonary embolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.J Thromb Haemost. 2025 Dec 5:S1538-7836(25)00844-X. doi: 10.1016/j.jtha.2025.10.036.
- Age-Adjusted D-Dimer Cutoff Levels to Rule Out Deep Vein Thrombosis.JAMA. 2026 Jan 5. doi: 10.1001/jama.2025.21561.
- Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial.Circulation. 2026 Jan 6;153(1):21-34. doi: 10.1161/CIRCULATIONAHA.125.077232. Epub 2025 Nov 3.